The HemoCue blood glucose analyser was investigated with particular respect to its susceptibility to influence by the haematocrit of the blood specimen. The red cells and plasma of fresh blood samples were separated and then recombined in proportions to give a range of haematocrit values and the resulting specimens assayed for glucose. The HemoCue exhibited no appreciable influence of haematocrit. The instrument was easy to use, stable and had good precision (CV 1'8%). However, results tended to be a little higher than those produced by a conventional laboratory analyser on whole blood and it is understood that the factory calibration of newer HemoCue instruments has been modified to correct for this.
SUMMARY. The HemoCue blood glucose analyser was investigated with particular respect to its susceptibility to influence by the haematocrit of the blood specimen. The red cells and plasma of fresh blood samples were separated and then recombined in proportions to give a range of haematocrit values and the resulting specimens assayed for glucose. The HemoCue exhibited no appreciable influence of haematocrit. The instrument was easy to use, stable and had good precision (CV 1'8%). However, results tended to be a little higher than those produced by a conventional laboratory analyser on whole blood and it is understood that the factory calibration of newer HemoCue instruments has been modified to correct for this.
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Several reports have drawn attention to the influence of haematocrit on near-patient testing systems for whole blood glucose that involve reagent strips.':" In some cases, the error introduced can be sufficient to invalidate the glucose result," and this has led to concern about the wisdom of using these techniques in certain clinical situations and in diabetes clinics. A new near-patient blood glucose testing system, the HemoCue, has recently been introduced. It employs a different assay principle and this study was designed to assess its susceptibility to influence by the haematocrit of the blood specimen.
The HemoCue blood glucose system is manufactured by HemoCue AB of Sweden and marketed in the UK by HemoCue Ltd (Sheffield, UK). It is based on a dedicated photometer that accepts special disposable plastic rnicrocuvettes containing a mixture of dry chemicals that will react with glucose in a blood specimen to produce a coloured product that can be quantitated by the photometer. Only 5 p,L of whole blood is required and may be taken up from a finger-prick directly into the self-filling cuvette. Alternatively, blood anticoagulated with EDTA, sodium fluoride, oxalate or heparin is also claimed to be acceptable. Once the cuvette is filled, it must be inserted into the photometer within 40 s. Thereafter, measurement is automatic, taking between 40 and 90 240 s for the result to be displayed, depending on glucose concentration. Higher concentrations take longer than lower ones.
The photometer can be mains-or batterypowered. Absorbance is measured at two wavelengths, 660 nm and 840 nm, to compensate for turbidity. A photometer check cuvette is provided to monitor instrument performance. The response of the system is claimed to be linear at blood glucose concentrations between 2· 0 and 22' 0 mmollL. The reagent microcuvettes have a 6-month shelflife from date of manufacture, if stored sealed at between 2°and 8°C. Once opened, the shelflife is 30 days according to the information supplied by the manufacturer.
Although designed for near-patient testing, the HemoCue is more suitable for professional use in diabetes clinics, etc., than for personal use by patients. Measuring approximately 210 x 160 x 80 mm, it is too bulky to carry conveniently on the person, but it is a compact bench-top instrument. Its price, about £600 excluding VAT, also tends to restrict it to professional use. The cuvettes are 60 peach.
The reagent mixture in the cuvettes comprises saponin, NAD, methylthiazolyldiphenyl tetrazolium (M'I'T), sodium fluoride, glucose dehydrogenase, diaphorase and mutarotase. The method is based on that described by Banauch et al. 6 The aspirin lyses the erythrocytes and the a.-D -Glucose mutarotase catalyses the conversion of a-Dglucose into fj-D-glucose, which reacts in the presence of glucose dehydrogenase to convert NAD to NADH. Diaphorase then catalyses the reduction of MIT in the presence of NADH to produce a coloured formazan in amounts proportional to the glucose concentration. The reaction sequence is summarized in Fig. 1 .
RESULTS
The results for the three specimens are summarized graphically in Figs 2-4. The marked effect of haematocrit on the Ames Glucostix/Glucometer method can be seen in all three instances. In contrast, the HemoCue result was largely unaffected, certainly in specimens 1 and 3. Specimen 2 actually exhibited a slight rise in measured glucose with increasing haematocrit.
Comparison of whole blood and plasma results on the YSI analyser showed divergence at higher haematocrit values except for specimen 2, where the plasma result decreased in parallel with the whole blood figure.
Although the HemoCue instrument was not calibrated for glucose measurement in plasma, a comparison of plasma glucose results on the YSI, HemoCue and Analox instruments demonstrated reasonable agreement between them and the HemoCue whole blood results were not appreciably lower than the HemoCue plasma results. Furthermore, it was noticeable that the HemoCue whole haematocrit level being done consecutively by the different methods. On the other hand, measurements at different haematocrit levels were done randomly to avoid introducing an artefactual progressive change in glucose result through the haematocrit range.
Three separate blood specimens with different glucose concentrations were subjected to the entire procedure described above. 
METHOD
The influence of haematocrit on the HemoCue glucose results was investigated by collecting venous blood samples into heparinized containers, centrifuging them to separate plasma from cells, then recombining aliquots of plasma and cells in different proportions to give blood samples with a wide range of haematocrit values. After thoroughly mixing the recombined fractions, measurements of haematocrit and glucose were made on each sample. For comparison purposes, glucose measurements were performed using the YSI-2300 STAT analyser (Clandon Scientific, Hampshire, UK) and the Ames Glucometer II with Glucostix test strips (Miles, Slough, UK). Some measurements of plasma glucose were also performed using the Analox GM? analyser (Analox, London, UK).
To minimize any effect of glycolysis, an effort was made to perform all glucose assays as quickly as possible, measurements at a particular 
DISCUSSION
The HemoCue analyser is clearly not subject to the same haematocrit effect that besets several of the other near-patient glucose testing systems. The strip-test methods usually depend on the reagents on the strip reacting with plasma that has passed through a porous membrane that retains red cells on the other side of it. The rate of permeation by the plasma can be influenced by the haematocrit of the whole blood sample and thus affect the rate of colour development. In the HemoCue cuvettes there is no membrane separation of red cells and plasma. The colour reaction is performed directly on lysed whole blood and the presence of different amounts of haemoglobin in the reaction mixture appears to have little, if any, effect. In one specimen a slight rise in the glucose result occurred with increasing haematocrit. This is the opposite of the effect observed with reagent strips and one could speculate that the increasing colour due to the haemoglobin might be contributing to this if the photometer were not adequately blanking it. No evidence for that is presented here, but it is a possibility in the HemoCue technique where the lysed cells and all the haemoglobin are retained in the reaction cuvette, compared with the situation with reagent strips where the red cells are wiped or blotted off before a reading is taken.
The divergence of YSI analysed whole blood and plasma glucose results with increasing haematocrit is to be expected and is in keeping with the common knowledge that plasma glucose may be approximately 15% higher than whole blood glucose at a normal haematocrit. The closer correlation seen in specimen 2 is less easy to explain, but probably occurred because, owing to shortage of specimen, the plasma measurements were made after the whole blood measurements and involved a short delay while the specimens were centrifuged. Thus, additional glycolysis might have occurred, especially in the tubes with the larger proportion of red cells.
The precision of the HemoCue instrument appeared to be very good, but there was some doubt as to its accuracy as whole blood results seemed to be a little high and more like those for plasma measurements on other laboratory analysers. When this was reported to the distributor, it became apparent that other workers had reported similar findings and that newer HemoCue models were being modified to give slightly lower results. This was expected to bring them more in line with blood figures tended to compare better with the YSI plasma results than with the YSI whole blood values.
During the study, an estimate of betweenbatch imprecision for the HemoCue was obtained by assaying two control sera with different glucose concentrations on 20 different occasions. At a mean level of 5· 65 mmollL, standard deviation was O· 11 mmollL and CV I ·86070. At a mean of 14· 09 mmollL, SD was 0·26 mmollL and CV 1·81%. While this study was not intended as a full-scale evaluation of the HemoCue blood glucose analyser, as this is underway elsewhere, a few comments about its performance are indicated. It is a very easy-to-use instrument that proved to be very stable during the investigation period and precision was good. Specimens with high glucose concentrations seem to take a long time to produce a result (about 240 s), but apart from that, the main disadvantage is probably the cost. A slightly annoying feature is the lack of a memory facility for the last result, particularly as the display is cleared after 3 or 4 min and no audible signal is given either to warn of this or to indicate when the result is initially displayed.
It is very easy to contaminate the sliding cuvette-holder with blood and reagent from the tip of the cuvette if the latter is not wiped before insertion. However, it is equally easy to clean the slider, which is removable. Taking everything into consideration, the HemoCue blood glucoseanalyser promises to be a good instrument for clinic use, its results being insignificantly affected by haematocrit and its precision being considerably better than that of most strip testing systems.
